Ruxolitinib

Overview

Ruxolitinib is a small molecule Janus kinase inhibitor used to treat myelofibrosis and polycythemia vera. It functions by inhibiting the JAK1 and JAK2 proteins, interfering with cytokine signaling involved in hematological malignancies.

API suppliers (2)

Suppliers of Ruxolitinib backed by a verifiable FDA Type II Drug Master File. Source: FDA quarterly DMF list.

• MSN Laboratories Private LimitedIndia3 active DMF
• Dr. Reddy's Laboratories Ltd.India2 active DMF

Patent & exclusivity (US)

Per the FDA Orange Book (11 approved US products), the latest listed US patent on Ruxolitinib expires 4 May 2041 and exclusivity 22 Mar 2029. Generic API sourcing typically opens up once these lapse.

Chemical identity

IUPAC name

propanoic acid

Canonical SMILES

CCC(=O)O

InChIKey

XBDQKXXYIPTUBI-UHFFFAOYSA-N

Therapeutic areas